ABVC BioPharma, Inc. (ABVC)
1.01
-0.03
(-2.88%)
USD |
NASDAQ |
Oct 30, 10:28
ABVC BioPharma Enterprise Value : 31.57M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 31.57M |
| October 28, 2026 | 32.86M |
| October 27, 2026 | 31.83M |
| October 26, 2026 | 31.83M |
| October 23, 2026 | 31.57M |
| October 22, 2026 | 31.76M |
| October 21, 2026 | 30.54M |
| October 20, 2026 | 28.74M |
| October 19, 2026 | 28.22M |
| October 16, 2026 | 28.43M |
| October 15, 2026 | 28.80M |
| October 14, 2026 | 31.06M |
| October 13, 2026 | 30.00M |
| October 12, 2026 | 30.02M |
| October 09, 2026 | 30.54M |
| October 08, 2026 | 30.03M |
| October 07, 2026 | 30.54M |
| October 06, 2026 | 29.77M |
| October 05, 2026 | 30.03M |
| October 02, 2026 | 30.80M |
| October 01, 2026 | 31.06M |
| September 30, 2026 | 32.09M |
| September 29, 2026 | 31.57M |
| September 28, 2026 | 31.83M |
| September 25, 2026 | 33.89M |
| Date | Value |
|---|---|
| September 24, 2026 | 32.86M |
| September 23, 2026 | 34.15M |
| September 22, 2026 | 34.67M |
| September 21, 2026 | 34.41M |
| September 18, 2026 | 34.67M |
| September 17, 2026 | 34.41M |
| September 16, 2026 | 32.60M |
| September 15, 2026 | 32.35M |
| September 14, 2026 | 30.54M |
| September 11, 2026 | 30.03M |
| September 10, 2026 | 29.93M |
| September 09, 2026 | 29.77M |
| September 08, 2026 | 32.09M |
| September 04, 2026 | 29.52M |
| September 03, 2026 | 30.54M |
| September 02, 2026 | 27.05M |
| September 01, 2026 | 26.04M |
| August 31, 2026 | 26.87M |
| August 28, 2026 | 26.16M |
| August 27, 2026 | 25.28M |
| August 26, 2026 | 23.10M |
| August 25, 2026 | 25.39M |
| August 24, 2026 | 26.42M |
| August 21, 2026 | 27.92M |
| August 20, 2026 | 27.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 278.45M |
| Perspective Therapeutics, Inc. | -99.43M |
| MiMedx Group, Inc. | 458.53M |
| Abbott Laboratories | 208.60B |
| AngioDynamics, Inc. | 500.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8105M |
| Total Expenses (Quarterly) | 0.7369M |
| EPS Diluted (Quarterly) | -0.0283 |
| Earnings Yield | -28.50% |
| Normalized Earnings Yield | -26.28 |